|447.10||-3.73||-0.83%||Vol 806.19K||1Y Perf -2.60%|
|Sep 22nd, 2023 16:00 DELAYED|
|- -||-0.01 0.00%|
|Target Price||568.44||Analyst Rating||Strong Buy 1.22|
|Potential %||27.14||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 46.85|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★ 39.44|
|Price Range Ratio 52W %||25.52||Earnings Rating||—|
|Market Cap||105.36B||Earnings Date||18th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||18th Oct 2023|
|Estimated EPS Next Report||8.45|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.16M|
|Avg. Monthly Volume||995.86K|
|Avg. Quarterly Volume||1.15M|
Elevance Health Inc. (NYSE: ELV) stock closed at 447.1 per share at the end of the most recent trading day (a -0.83% change compared to the prior day closing price) with a volume of 806.19K shares and market capitalization of 105.36B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Plans industry, Healthcare sector and employs 98200 people. Elevance Health Inc. CEO is Gail Koziara Boudreaux.
The one-year performance of Elevance Health Inc. stock is -2.6%, while year-to-date (YTD) performance is -12.84%. ELV stock has a five-year performance of 71.59%. Its 52-week range is between 412 and 549.52, which gives ELV stock a 52-week price range ratio of 25.52%
Elevance Health Inc. currently has a PE ratio of 18.60, a price-to-book (PB) ratio of 3.16, a price-to-sale (PS) ratio of 0.96, a price to cashflow ratio of 10.00, a PEG ratio of -, a ROA of 6.18%, a ROC of -% and a ROE of 17.32%. The company’s profit margin is 4.34%, its EBITDA margin is -%, and its revenue ttm is $116.67 Billion , which makes it $488.49 revenue per share.
Of the last four earnings reports from Elevance Health Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $8.45 for the next earnings report. Elevance Health Inc.’s next earnings report date is 18th Oct 2023.
The consensus rating of Wall Street analysts for Elevance Health Inc. is Strong Buy (1.22), with a target price of $568.44, which is +27.14% compared to the current price. The earnings rating for Elevance Health Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Elevance Health Inc. has a dividend yield of 1.09% with a dividend per share of $5.12 and a payout ratio of -%.
Elevance Health Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 42.30, ATR14 : 8.48, CCI20 : 6.70, Chaikin Money Flow : -0.09, MACD : -3.39, Money Flow Index : 49.45, ROC : 0.25, RSI : 47.06, STOCH (14,3) : 60.28, STOCH RSI : 0.74, UO : 52.15, Williams %R : -39.72), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Elevance Health Inc. in the last 12-months were: Charles Morgan Kendrick (Sold 2 314 shares of value $1 069 577 ), Dixon Robert L JR (Sold 310 shares of value $147 780 ), Gloria M. McCarthy (Sold 15 098 shares of value $6 714 978 ), Kendrick Charles (Sold 2 314 shares of value $1 069 577 )
Wed, 19 Jul 2023 13:10 GMT Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and BeiGene (BGNE)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.